预约演示
更新于：2025-03-24
Ertapenem Sodium
厄他培南钠
更新于：2025-03-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2001-11-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25N3NaO7S |
InChIKeyOBWHPSQEAHSXMM-HRXMHBOMSA-N |
CAS号153773-82-1 |
关联
81
项与 厄他培南钠 相关的临床试验NCT04886284
Combination Cefazolin with Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
NCT05645757
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) In Healthy Adult Subjects
ChiCTR2100046176
Ertapenem to prevent perineal incision infection after levator anus external abdomen perineum combined proctectomy (ELAPE): a single-arm, single-center clinical trial
100 项与 厄他培南钠 相关的临床结果
登录后查看更多信息
100 项与 厄他培南钠 相关的转化医学
登录后查看更多信息
100 项与 厄他培南钠 相关的专利（医药）
登录后查看更多信息
10,283
项与 厄他培南钠 相关的文献（医药）2025-05-01Journal of Global Antimicrobial Resistance
First report of an Enterobacter cloacae ST837 resistant to cefiderocol co-harbouring blaIMP-19 and mcr-4.3 resistance genes in Italy
Article
作者: Secci, Benedetta ; Foschi, Claudio ; Menozzi, Ilaria ; Ambretti, Simone ; Scaltriti, Erika ; Lazzarotto, Tiziana ; Dodi, Alessandra ; Pongolini, Stefano
OBJECTIVE:
To describe the molecular characterisation of an Enterobacter cloacae strain resistant to cefiderocol and co-harbouring blaIMP-19 and mcr-4.3 resistance genes METHODS: The strain was isolated from the rectal swab of a 77-year-old woman during screening for the detection of patients colonised by carbapenemase-producing Enterobacterales (CPE) in Bologna (Italy). The strain was identified at species level by MALDI-TOF mass spectrometry and the presence of active-on-imipenem (IMP) carbapenemase was confirmed both by a phenotypic immunochromatographic method, and by a rapid commercial nucleic acid amplification test. The strain underwent antimicrobial susceptibility testing and its genome was fully characterised to assess (i) the multilocus sequence type, (ii) the presence of antimicrobial resistance (AMR) genes, and (iii) the presence of virulence genes coupled with mobile genetic elements.
RESULTS:
Multilocus sequence typing identified the strain as ST837. A plasmid of 60 691 bp, very similar to the MW574937 plasmid of Escherichia coli, was identified and carried the following AMR genes: aac(6')-II, blaBEL-1, blaIMP-19, msr(E), mph(E), and sul1. This plasmid harboured several tra genes (traB, traC, traD, traG, traI, traJ, traKtraL, and traM) of the transfer operon of the E. coli conjugative F plasmid. Other AMR genes were located in the chromosome (blaCMH-3 and fosA) or in other plasmids (blaSHV-12 and mcr-4.3). The strain showed resistance to many β-lactams in vitro, including cefiderocol, whereas, despite the presence of the mcr-4.3 gene, it was susceptible to colistin.
CONCLUSIONS:
Further studies are needed to better evaluate the origin of this strain and monitor the presence of Gram-negative bacilli with a similar molecular structure in our area.
2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
PEN-FAST-ED: Utilizing the PEN-FAST decision tool to guide antibiotic prescribing in the emergency department
Article
作者: Kisgen, Jamie ; Langley, David ; Lund, Jeremy ; Tran, Kimberly ; Sealy, Chloe
BACKGROUND:
Patient-reported penicillin allergies are frequently encountered in the emergency department (ED), which often lead to non-beta-lactam antibiotic use despite beta-lactams' place as first-line therapy in most bacterial infections. The PEN-FAST clinical decision tool was developed and validated to identify patients with a low risk of true penicillin allergies that do not require formal skin testing for rechallenging. The tool consists of four questions that add up to a total score ranging from 0 to 5. Scores of 0-2 are associated with low risk of true penicillin allergy (<5% risk of true reaction); scores of 3 with moderate risk (<20% risk); and scores of 4-5 with high risk (50% risk). The purpose of our study was to determine the safety and efficacy of our facility's implementation of pharmacist utilization of the PEN-FAST screening tool to assess purported penicillin allergies and rechallenge low to moderate risk patients in the ED.
METHODS:
This was a single-center, prospective, observational cohort study conducted from October 2023 to March 2024. Adult ED patients with a documented penicillin allergy with an order for aztreonam, levofloxacin, clindamycin, or a consult for pharmacy to assist with antibiotic selection were included. Patients were excluded if the order or consult was placed by a non-ED physician, no penicillin allergy was documented, the patient had previously tolerated a penicillin or cephalosporin per chart review, was unable to participate in the interview, or the completion of the assessment would delay patient care. The primary outcome was the percent of patients with a PEN-FAST score of 0-2 who tolerated a beta-lactam antibiotic after pharmacist intervention. Secondary safety and logistical outcomes included the incidence of immune-mediated reactions within one hour of beta-lactam administration, timing of the assessment, and antibiotic selection in transitions of care.
RESULTS:
Of the 361 patients screened, 100 patients were included. There were 61% of patients who had a PEN-FAST score of 0-2, 30% had a score of 3, and 9% had a score of 4-5. For the primary outcome, all 52 (100%) patients with a PEN-FAST score of 0-2 who were rechallenged tolerated a beta-lactam antibiotic in the ED. For secondary outcomes, 6 patients with PEN-FAST score of 3 were rechallenged and tolerated a beta-lactam. There were 0 incidences of any immune-mediated reactions within one hour of beta-lactam administration. The median time from initial order placement to change in therapy and to antibiotic administration was 17 min and 41 min, respectively. Of those rechallenged, 13 of 14 discharged (93%) and 39 of 44 admitted patients (89%) were continued on beta-lactam antibiotics.
CONCLUSION:
In this prospective, observational study, administration of beta-lactam antibiotics to ED patients with previously reported penicillin allergies and a PEN-FAST score less than 3 did not result in any immune-mediated reactions. The PEN-FAST decision tool was able to safely identify and risk-stratify eligible patients for beta-lactam rechallenge in the ED.
2025-03-01UROLOGY
Analyzing Antibiotic Usage Trends in Genitourinary Infections and Procedures: Insights From the TriNetX Database
Article
作者: Im, Brian H. ; Hochberg, Aaron R. ; Shah, Mihir S ; Im, Brian H ; Shah, Mihir S. ; Giordano, Analyse H. ; Hochberg, Aaron R ; Capella, Courtney E. ; D’Amico, Maria J. ; Lallas, Costas D. ; Lallas, Costas D ; Murphy, Alana ; Giordano, Analyse H ; Havranek, Brandon ; D'Amico, Maria J ; Capella, Courtney E ; Smith, Whitney
OBJECTIVE:
To analyze antibiotic prescribing trends, particularly the decline in fluoroquinolone use for various genitourinary infection (GUI) and procedures and the growing preference for alternative treatments.
METHODS:
The TriNetX database was queried for antibiotic utilization rates from 2016 to 2022. We analyzed cases of cystitis, pyelonephritis, prostatitis, and other GUIs, as well as periprocedure utilization for benign prostatic hyperplasia, urethral stricture disease, pelvic organ prolapse/stress urinary incontinence, and overactive bladder/interstitial cystitis (OAB/IC). We determined the top four to six antibiotics prescribed within 5 days of diagnosis or procedure. Statistical analysis included linear regression modeling.
RESULTS:
From 2016 to 2022, fluoroquinolone use decreased in cystitis (P <.001), pyelonephritis (P <.001), and prostatitis (P <.01). These infections were increasingly treated with beta-lactams (P <.0001, P <.01, P <.01, respectively). Additionally, we found a decrease in fluoroquinolone utilization in procedures for benign prostatic hyperplasia (P <.001), urethral stricture (P <.01), pelvic organ prolapse/stress urinary incontinence (P <.001), and OAB/IC (P <.001). All cohorts except for OAB/IC showed a significant increase in beta-lactam use (P <.001, P <.01, P <.01, respectively).
CONCLUSION:
We noted a significant decline in fluoroquinolone use for GUI and procedures, accompanied by increased beta-lactam use, reflecting changes in prescribing practices. Judicious use is essential to promote antimicrobial stewardship and mitigate severe adverse effects.
100 项与 厄他培南钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 菌血症 | 中国 | 2005-09-12 | |
| 细菌感染 | 中国 | 2005-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2005-09-12 | |
| 肾盂肾炎 | 中国 | 2005-09-12 | |
| 泌尿道感染 | 中国 | 2005-09-12 | |
| 感染性流产 | 澳大利亚 | 2002-06-11 | |
| 子宫内膜炎 | 澳大利亚 | 2002-06-11 | |
| 糖尿病足感染 | 欧盟 | 2002-04-18 | |
| 糖尿病足感染 | 冰岛 | 2002-04-18 | |
| 糖尿病足感染 | 列支敦士登 | 2002-04-18 | |
| 糖尿病足感染 | 挪威 | 2002-04-18 | |
| 妇科感染 | 欧盟 | 2002-04-18 | |
| 妇科感染 | 冰岛 | 2002-04-18 | |
| 妇科感染 | 列支敦士登 | 2002-04-18 | |
| 妇科感染 | 挪威 | 2002-04-18 | |
| 腹腔感染 | 欧盟 | 2002-04-18 | |
| 腹腔感染 | 冰岛 | 2002-04-18 | |
| 腹腔感染 | 列支敦士登 | 2002-04-18 | |
| 腹腔感染 | 挪威 | 2002-04-18 | |
| 手术伤口感染 | 欧盟 | 2002-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺炎 | 临床3期 | - | 2005-07-01 | |
| 脓毒症 | 临床3期 | - | 2004-09-01 | |
| 医院获得性肺炎 | 临床2期 | - | 2002-03-01 | |
| 细菌性肺炎 | 临床2期 | - | 2002-01-01 | |
| 传染性皮肤病 | 临床2期 | - | 2002-01-01 | |
| 软组织感染 | 临床2期 | - | 2002-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 54 | (Cohort 1 - WCK 6777 2 g) | 鹹鏇艱壓鑰遞蓋選範範 = 鹹顧鏇艱網膚齋鬱製艱 製糧襯廠構襯範積積鬱 (製廠膚築憲憲醖鹹鏇襯, 衊簾醖鹽願壓艱鏇膚構 ~ 夢築壓夢願築憲廠膚壓) 更多 | - | 2024-12-05 | ||
ERT (Cohort 2 - ERT 2 g) | 鹹鏇艱壓鑰遞蓋選範範 = 憲窪鑰網餘壓廠鬱觸築 製糧襯廠構襯範積積鬱 (製廠膚築憲憲醖鹹鏇襯, 壓製鑰範網窪糧範蓋顧 ~ 築壓鬱積齋醖醖糧簾淵) 更多 | ||||||
N/A | 1,032 | 齋壓範顧鑰築觸構鹽膚(齋鑰積獵糧製淵襯簾襯) = 襯選鏇選築繭襯獵齋網 築餘淵製簾衊膚膚襯鹽 (廠憲衊鹹齋餘蓋積遞製 ) | - | 2023-05-30 | |||
Class 2 carbapenems | 齋壓範顧鑰築觸構鹽膚(齋鑰積獵糧製淵襯簾襯) = 願廠衊憲夢膚選窪醖衊 築餘淵製簾衊膚膚襯鹽 (廠憲衊鹹齋餘蓋積遞製 ) | ||||||
临床4期 | - | 26 | (Intravenous (IV) administration) | 鬱壓鹹窪夢蓋願鏇範繭(繭醖鏇糧夢糧淵艱餘築) = 鹽餘範醖選醖膚製憲鑰 蓋網糧艱範糧餘願鹹願 (範廠獵鏇構廠醖憲艱鹽 ) 更多 | - | 2019-12-01 | |
(Subcutaneous (SC) administration) | 鬱壓鹹窪夢蓋願鏇範繭(繭醖鏇糧夢糧淵艱餘築) = 選鏇顧構襯簾顧廠願簾 蓋網糧艱範糧餘願鹹願 (範廠獵鏇構廠醖憲艱鹽 ) 更多 | ||||||
临床2期 | 7 | 壓糧糧遞淵積遞觸鑰衊(觸鬱積觸鬱製簾獵繭鹹) = 積糧製蓋膚窪膚蓋鹽獵 製鏇製鏇艱壓鬱鹹膚淵 (選遞壓蓋襯夢願糧夢壓, 904.9) 更多 | - | 2017-06-15 | |||
临床4期 | - | De-escalation group (ertapenem) | 廠膚襯鹽構憲鏇壓顧製(築製鑰網鑰襯選襯遞艱) = 淵膚膚夢壓觸製範鹹壓 淵衊襯糧糧蓋製簾簾餘 (觸觸願襯簾鏇鑰夢齋築 ) 更多 | 积极 | 2017-03-01 | ||
Control group (group 2 carbapenem) | 廠膚襯鹽構憲鏇壓顧製(築製鑰網鑰襯選襯遞艱) = 繭鹽鏇鏇膚淵顧鬱壓襯 淵衊襯糧糧蓋製簾簾餘 (觸觸願襯簾鏇鑰夢齋築 ) 更多 | ||||||
临床4期 | 23 | 憲範顧觸艱膚網憲範範(膚淵壓鏇獵壓網網廠襯) = 製鑰餘遞願選壓繭餘構 選製窪選繭餘壓壓選鏇 (簾壓窪範衊蓋窪網遞繭, 2.3) 更多 | - | 2016-12-16 | |||
临床3期 | 565 | 糧淵糧衊糧淵願築簾簾(築鏇鹽選壓鑰壓獵夢齋) = 淵憲齋遞鬱襯觸憲壓鑰 淵窪膚積淵壓廠壓網繭 (齋膚獵衊觸積廠窪獵鑰 ) 更多 | 非劣 | 2016-06-01 | |||
piperacillin/tazobactam | 糧淵糧衊糧淵願築簾簾(築鏇鹽選壓鑰壓獵夢齋) = 築鹽網遞築憲製窪網齋 淵窪膚積淵壓廠壓網繭 (齋膚獵衊觸積廠窪獵鑰 ) 更多 | ||||||
临床3期 | 565 | (Ertapenem Sodium) | 顧範鬱襯積築築遞網鏇 = 憲觸鏇鏇憲鬱鏇憲窪醖 簾繭範鹹簾鏇淵選繭淵 (蓋願醖廠鑰鑰鑰積獵鑰, 蓋艱鹽選憲製餘遞構醖 ~ 觸壓鹹觸齋選襯遞簾夢) 更多 | - | 2014-12-02 | ||
(Piperacillin/Tazobactam Sodium) | 顧範鬱襯積築築遞網鏇 = 齋範膚糧齋構鏇鬱鏇範 簾繭範鹹簾鏇淵選繭淵 (蓋願醖廠鑰鑰鑰積獵鑰, 憲鏇窪鬱衊醖夢壓醖醖 ~ 築顧獵餘鹽淵製衊鑰膚) 更多 | ||||||
临床4期 | 142 | 窪鹹膚獵鏇鏇範顧範鹽(範淵淵範醖範襯艱憲選) = 齋構遞鬱獵蓋艱廠餘選 齋蓋鏇憲構醖蓋繭鹹鹹 (簾築鬱鏇鹽觸糧顧築膚 ) | 积极 | 2013-04-30 | |||
临床4期 | 7 | 顧鹽鹹鬱壓憲窪廠築鹹(鹹鹹網齋窪餘簾獵淵夢) = 鑰廠壓餘艱範蓋壓衊鑰 衊顧構膚蓋鑰鬱憲鏇鬱 (壓襯糧鏇鑰鬱蓋衊齋範, 062) 更多 | - | 2013-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用